This cross-sectional study was conducted to determine the serum lipid profiles in chronic obstructive pulmonary disease (COPD) patients and its correlation with the severity of COPD in the Department of Respiratory Medicine at Bangabandhu Sheikh Mujib Medical University. A total of 100 spirometric-confirmed cases of COPD were included. Fasting blood samples for lipid profiles were collected. To identify the association between severity of COPD with lipid profiles Pearson’s correlation was used. Further multiple linear regression was done to identify the relation. The mean (standard deviation) age of the patients was 59.0 (10.7)years. The ratio of males and females was 19:1. The mean forced expiratory volume (liters) in 1 second (FEV1) was 55.1 (18.1). Most of the patients had stage II (48%) and stage III (36%) airflow obstruction. Plasma level of total cholesterol and triglyceride tend to increase, statistically non-significant, with stages of COPD. However, the association of plasma lipids becomes statistically significant with FEV1 when the effects of age, BMI, pack-year smoking, duration of illness are accounted in multiple linear regression analysis. Bangabandhu Sheikh Mujib Medical University Journal 2022;15(4):37-41
Introduction: Advanced Non-Small Cell Lung Cancer (NSCLC) is a serious condition characterized by the spread of cancer beyond the lungs, commonly adenocarcinoma and squamous cell carcinoma. Palliative chemotherapy is used to manage advanced NSCLC, focusing on relieving symptoms and improving quality of life rather than curing the disease. Paclitaxel-Carboplatin and Gemcitabine-Carboplatin are commonly used regimens for palliative chemotherapy in advanced NSCLC. Comparing the toxicities of these two regimens is important to determine which one has fewer side effects for patients. Aim of the Study: The aim of the study was to compare the toxicities of Paclitaxel-Carboplatin and Gemcitabine -Carboplatin as palliative chemotherapy for Advanced Non-Small Cell Lung Cancer. Methods: This Quasi- Experimental study was conducted at the Department of Medical Oncology, Combined Military Hospital, Dhaka, Bangladesh, the National Institute of Cancer Research & Hospital (NICRH), Mohakhali, Dhaka, Bangladesh, and the Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka, Bangladesh. The study duration was 10 months, from January 2022 to October 2022. During this period, a total of 74 participants were divided into two equal groups, Arm-A receiving the Paclitaxel-Carboplatin treatment regimen, and Arm-B receiving the Gemcitabine- Carboplatin treatment regimen. Result: The majority of participants in both Arm-A and Arm-B were in the age group of 51-60 years (40.54% in Arm-A, 43.24% in Arm-B) with an overall mean age of 58.35 years in Arm-A and 57.54 years in Arm-B. An overall male prevalence was observed, with 78.38% of participants in Arm-A and 70.27% in Arm-B being male. The majority of participants had an ECOG status of 1 (45.95% in Arm-A, 59.46% in Arm-B). Risk factors such as smoking and various lung diseases were present among participants, but there was no significant difference between the two arms. After 6 weeks of follow-up, 62.16% of Arm-A and 56.76% of ...
Background: The outcome of treatment for advanced gastric carcinoma can vary depending on a number of factors, including the stage and aggressiveness of the cancer, the patient's overall health, and their response to treatment. In general, the prognosis is poor, with a median overall survival of less than one year. Quality of life (QOL) is an important consideration for patients with advanced gastric carcinoma, as they may experience a range of symptoms such as pain, fatigue, and difficulty eating. This study aimed to evaluate the post-treatment outcomes and QOL in patients with inoperable advanced gastric carcinoma after treatment with cisplatin-capecitabine and with oxaliplatin-capecitabine. Methods: This Quasi-experimental study was conducted at the department of oncology, Bangabandhu Sheikh Mujib medical university, Dhaka, Bangladesh. The study duration was 1 year, from February 2021 to March 2022. During this period, a total of 64 cases of advanced gastric cancer were divided in two equal groups, arm A who had received cisplatin capecitabine, and arm B who received oxaliplatin capecitabine. Result: The mean age at diagnosis was 55.85 and 56.76 respectively. The majority of the patients, 43.8% in arm A and 50% in arm B, ranged in age from 61 to 70. The gender distribution was similar, 78% and 69% of patients in arm A and B respectively were male. Both groups had the majority of patients receiving an ECOG performance rating of 2, with 68.8% in arm A and 59.4% in arm B, and the liver being the most common metastatic site for 56.3% in arm A and 50.0% in arm B. The most frequent risk factor was Helicobacter pylori infection, observed in 68.8% of arm A and 78.1% of arm B. The most common primary tumor site was the antrum, with 50% and 53.1% patients in arm A and B respectively had the primary tumor in the antrum of the stomach. Conclusions: In inoperable advanced gastric cancer, the cisplatin-capecitabine regimen is equally effective as oxaliplatin-capecitabine in terms of disease outcome. Furthermore, the cisplatin-capecitabine regimen is less costly than the combination of oxaliplatin-capecitabine, and provides almost similar QOL. As a result, the cisplatin-capecitabine regimen could be utilized as an alternate choice in patients who are unable to afford an oxaliplatin-based regimen.
Background: The pattern of bacterial infection in acute exacerbation of bronchiectasis is varied with geographical area and lobar distribution of bronchiectasis. The exact pattern of bacterial infection in acute exacerbation of bronchiectasis according to lobar distribution is not known in our country. This study aimed to investigate the pattern of bacterial infection in acute exacerbation of bronchiectasis according to lobar distribution. Methods: A total of eighty-four patients diagnosed with acute exacerbation of bronchiectasis were included in this cross-sectional study in the department of respiratory medicine, Bangabandhu Sheikh Mujib Medical University. Sputum culture and real-time polymerase chain reaction were used to characterize the bacterial profile and high-resolution computed tomography scans for the location of the bronchiectasis. Before enrolment, informed written consent was obtained from the participants. Results: The mean (SD) age of this study population was 47.89 (±14.95) years, 29.8% were female and 60.7% were a non-smoker. Bronchiectasis was more common in the right middle lobe (63.1%), followed by the right lower lobe (44%), and the left lower lobe (42%). Bacteria were isolated in 66% of patients and Gram-negative bacteria were predominant (78.6%). Pseudomonas aeruginosa (25%) and Klebsiella pneumoniae (17.9%) were the most common bacteria. Conclusions: Pseudomonas aeruginosa was identified predominantly in the right upper lobe, right middle lobe, left upper lobe, and bilateral upper lobe and Klebsiella pneumoniae was in the right lower lobe, left lower lobe, and bilateral lower lobe.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.